Exploration of Dilated Cardiomyopathy for Biomarkers and Immune Microenvironment: Evidence From RNA-seq

Background: The pathogenic mechanism of Dilated Cardiomyopathy (DCM) remain to be defined. This study aimed to identify hub genes and immune cells that could serve as potential therapeutic targets for DCM. Methods: : We downloaded four data sets from the Gene Expression Omnibus (GEO) database, GSE141910, GSE3585, GSE42955 and GSE79962. Weighted gene coexpression network analysis (WGCNA) and differential expression analysis were performed to identified genes panel related DCM. Meanwhile, CIBERSORT algorithm was used to estimate the immune cells in DCM tissues. Multiple machine learning approaches were used to screen the hub genes and immune cells. Finally, the diagnostic value of the hub genes was assessed by receiver operating characteristic (ROC) analysis. Results: : FRZB and EXT1 were identified as hub biomarkers, and the ROC curves suggested an excellent diagnostic ability of above genes for DCM. In addition, B cells naive was up-regulated in DMC tissues, while Eosinophils, Macrophages M2, and T cells CD4 memory were down-regulated in DMC tissues. Conclusion: These results indicated that FRZB and EXT1 could be used as promising biomarkers, and Eosinophils, Macrophages M2, T cells CD4 memory resting and B cells naive also may affect the occurrence of DCM.